Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
docetaxel + oxaliplatin + 5-fluorouracil
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
The combination of docetaxel, oxaliplatin, and 5-fluorouracil (DOF) is a chemotherapy regimen primarily used for the treatment of advanced or metastatic gastric cancer and gastroesophageal junction adenocarcinoma. Docetaxel is a microtubule-targeting agent that stabilizes microtubules and inhibits cell division. Oxaliplatin is a platinum-based compound that forms DNA crosslinks leading to apoptosis. 5-Fluorouracil (5-FU) is an antimetabolite that inhibits thymidylate synthase, disrupting DNA synthesis in rapidly dividing cells. This combination exploits different mechanisms to maximize cytotoxicity against cancer cells[1][6]. The regimen may be referred to as FLOT when leucovorin/folinic acid is added[2][7].
- Brand names
- Adrucil
- Other names
- DOF regimenFLOT (when combined with leucovorin/folinic acid)docetaxel, oxaliplatin, and 5-FU
02
Targets
TUBB (Tubulin (alpha and beta subunits))DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on docetaxel + oxaliplatin + 5-fluorouracil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on docetaxel + oxaliplatin + 5-fluorouracil.